News & Analysis on Clinical Trial Services & Contract Research And Development
A $30.1m drop in licence and research revenue and the expensive removal by rebel shareholders of its former CEO Gerard Soula last June have taken drug delivery company Flamel from a net profit of $12.5m (€10.3m) in 2004 to a net loss of $27.4m in...
Looking for an advantage in the high-value generics market and a boost to its contract development services for research-driven pharmaceutical companies, Swiss chemicals and pharmaceuticals group Schweizerhall has bought German drug delivery firm...
A new laboratory method, which looks for a spinal fluid protein, may identify people with the earliest stages of multiple sclerosis (MS), greatly increasing the effectiveness of drug therapies to treat the 10,000 Americans, who are diagnosed with MS...
In what is shaping up to be a new promising area in the verification of drugs, Analytical Spectral Devices (ASD) has received another patent for its RxSpec technology which uses near infrared spectroscopy (IR), as rival company CDEX is also targeting...
In its first venture outside the subcontinent, though certainly not the last of its kind for India pharma companies, contract pharmaceuticals manufacturer Kemwell has bought for an undisclosed sum Pfizer's production plant in Uppsala, looking to...
Filtration systems specialist Pall's net profit barely moved in Q2 compared to the similar period last year, up only $400,000 (€331,328) to $32.4m, still its Biopharmaceuticals business, driven by a steady demand in consumables, posted a 4 per cent...